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Abstract
Purpose SARS-CoV-2 is a recently emerged ß-coronavirus. Here we present the current knowledge on its epidemiologic 
features.
Methods Non-systematic review.
Results SARS-CoV-2 replicates in the upper and lower respiratory tract. It is mainly transmitted by droplets and aerosols from 
asymptomatic and symptomatic infected subjects. The consensus estimate for the basis reproduction number  (R0) is between 
2 and 3, and the median incubation period is 5.7 (range 2–14) days. Similar to SARS and MERS, superspreading events 
have been reported, the dispersion parameter (kappa) is estimated at 0.1. Most infections are uncomplicated, and 5–10% of 
patients are hospitalized, mainly due to pneumonia with severe inflammation. Complications are respiratory and multiorgan 
failure; risk factors for complicated disease are higher age, hypertension, diabetes, chronic cardiovascular, chronic pulmonary 
disease and immunodeficiency. Nosocomial and infections in medical personnel have been reported. Drastic reductions of 
social contacts have been implemented in many countries with outbreaks of SARS-CoV-2, leading to rapid reductions. Most 
interventions have used bundles, but which of the measures have been more or less effective is still unknown. The current 
estimate for the infection’s fatality rate is 0.5–1%. Using current models of age-dependent infection fatality rates, upper and 
lower limits for the attack rate in Germany can be estimated between 0.4 and 1.6%, lower than in most European countries.
Conclusions Despite a rapid worldwide spread, attack rates have been low in most regions, demonstrating the efficacy of 
control measures.
Keywords SARS-CoV-2 · COVID-19 · Pandemic · Epidemiology · Basic reproduction number · Incubation period · 
Mortality · Infection fatality risk
Abbreviations
CFR  Case fatality rate
IFR  Infection fatality rate
R0  Basic reproduction number
Human infections with SARS-CoV-2 were first reported 
in late 2019, the syndrome was named Coronavirus-Dis-
ease-19 (COVID-19). Infections spread rapidly worldwide, 
in March 2020 WHO declared COVID as a new pandemic. 
Here we summarize the current knowledge regarding epi-
demiologic features and parameters of SARS-CoV-2 in a 
nonsystematic review. Numbers of infections and mortality 
rates were updated until end of August 2020 [1, 2]. A first 
epidemic wave could be observed in several countries, giv-
ing the opportunity to estimate attack rates of the first wave 
for some countries.
Transmission
SARS-CoV 2 replicates mainly in the upper and lower 
respiratory tract. Replication has also been detected in the 
GI tract, viral RNA can be present in peripheral blood in 
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severely ill patients [3]. Transmission occurs mainly through 
respiratory droplets and aerosols [4]. Transmission by other 
routes has not been convincingly demonstrated in contrast 
to SARS [5, 6].
One factor for the high infectivity of SARS-CoV2 is 
its replication in the upper respiratory tract. In contrast to 
SARS, SARS-CoV-2 can also be transmitted by asympto-
matic infected individuals [7, 8].
Basic reproduction number  R0, incubation 
period and superspreading
The basic reproduction number  R0 can be estimated by 
observation of infection chains, clusters of infection or by 
spread in a population. The current consensus estimate for 
 R0 for SARS-CoV-2 is between 2 and 3, higher estimates 
(up to 14.8) have been reported from single outbreaks 
namely the “Diamond Princess cruise ship [9–11].
The heterogeneity of estimates of  R0 can best be 
explained by the high interindividual variance of the likeli-
hood of transmission from a single case. SARS-CoV-2 has 
shown very effective transmission in several large clusters. 
In the first outbreak in Wuhan (mainly in healthcare set-
tings) was reported. In contrast, the household infection 
rates were low [4]. So called superspreading events have, 
meanwhile, also been reported outside of health care set-
tings, e.g., in religious gatherings [12].
This variance can be described by the overdispersion 
parameter k (kappa). The lower k, the higher is the vari-
ance of interindividual transmission rates (Table 1). Using 
current estimates of  R0 (2.5) and kappa (0.1) 60% of infec-
tions will not be transmitted, while 10% of infections are 
responsible for > 80% of transmissions [11].
Currently the conditions leading to superspreading are 
not fully characterized, especially the role of biological 
(e.g., viral load, loud voice) or social factors (e.g., number 
of contacts).
It is obvious that prevention of superspreading events 
will have a large impact on transmission.
The median incubation period is 5.7 days, 99% of all 
infections happen between day 2 and day 14 [13]. The 
latent period is probably 1 day shorter [13]. The median 
serial interval of infections has initially been estimated 
as high as 7.6 days, later observations put this parameter 
closer to 4 days (Table 1) [10, 14, 15].
Age distribution of cases
The number of cases in most countries is highest in the age 
group between 20 and 59 years. Outbreaks in China, Korea, 
Italy and Germany show different patterns (Fig. 1). In all 
outbreaks the numbers of infected children (age 0–9) have 
been small (Fig. 1) [2, 16–18]. In Germany the age specific 
incidence rates over the first wave of the epidemic show the 
highest initial incidence in the age group over 80 years and 
higher incidences in younger people in later stages of the 
epidemic (Fig. 2) [2].
Nosocomial and transmission in health care 
settings
Transmissions in health care settings, both nosocomial and 
to health care personnel have first been reported in the early 
period of the Wuhan outbreak. In most settings infection 
in the index patients was unknown and transmission was 
associated with emergency procedures, e.g., intubation [4].
Later in the outbreak most infections in health care work-
ers were not classified as health care associated but commu-
nity transmission. The rate of infected health care personnel 
in all cases was 2.7% in China, 11% in Italy and 5.8% in 
Germany [2, 4, 18]. In seroepidemiologic studies from Italy 
and Spain the seroprevalence of SARS-CoV-2 infection was 
approximately twice the rate of workers in other occupations 
(Italy 5.3% vs. 2.8%, Spain 10.2% vs. 4.8%, UK 11.7% vs. 
5.3%) [19-21]. Fortunately, the number and rate of severe 
cases and complications in contrast are low in this group 
[2, 4, 18].
Clinical spectrum, severity of disease 
and long‑term outcome
Infection with SARS-CoV has a broad clinical spectrum 
from asymptomatic, oligosymptomatic to moderate or even 
severe disease with multiorgan failure.
The rate of asymptomatic infections has been esti-
mated from intensive follow up in regional outbreaks and 
retrospectively in seroprevalence studies with rates of 
Table 1  Epidemiologic parameters of SARS-CoV-2
Parameter Value
Basic reproduction number  R0 2–3 (Consensus)
Range: 1.7–14.8
Dispersion coefficient (kappa) 0.1 (0.05–0.2)
Incubation period Median 5.7 d, 99% 





Fig. 1  Age distribution of COVID-19 cases in China, Korea, Italy and Germany
Fig. 2  Age specific weekly incidence (cases/100,000) of COVID 19 in Germany, week 10–34/2020
 B. Salzberger et al.
1 3
asymptomic infections ranging from 27 to 40% [20–22]. 
Overall, approximately 90% of infections are uncomplicated, 
oligosymptomatic or with moderate symptoms not leading 
to hospitalization.
Higher age, hypertension, chronic cardiac or pulmonary 
disease, and immunosuppression are risk factors for severe 
disease. Rates of hospitalization range in different popula-
tions between 4 and 7%. 25% of hospitalized patients require 
intensive care with a high rate of organ replacement therapy 
(75% invasive ventilation, 25% renal replacement therapy) 
[23-26].
Long term outcome, especially with severe lung disease 
and multiorgan failure is unknown, studies to determine the 
patterns of sequelae are ongoing.
How deadly is SARS‑CoV‑2?
One crucial parameter to determine the severity of a pan-
demic is the infection fatality rate IFR). Due to the high 
rate of uncomplicated infections symptomatic cases do 
not reflect the total number of infections. Thus, the case 
fatality rate (CFR) will be much higher than the IFR. In 
COVID-19, CFRs in different countries differ consider-
ably, mainly due to testing strategies and the age distribu-
tion of the national population (Tables 2, 3).
Investigators from the Imperial College, London, have 
first established a mathematical model to estimate age 
dependent case- and infection fatality rates from a high 
number of cases (Table 2). Other estimates have been 
Table 2  Age specific case-fatality rates in different nations and models for infection fatality rates
*Case-fatality-rate, by intensive contact tracking probably close to IFR
**Only community-dwelling people, institutionalized excluded
# Estimated with 90% still hospitalized, later corrected to 5.2%
Age (years) Case-fatality rates Infection-fatality rate (IFR) Modell
China Italy Germany Spain Südkorea* Indiana, USA** ENE, Spain International 
(Imperial College)
France
0–9 0% 0.1% 0.01% 0.3% 0% n.d  < 0.01% 0.0016% 0.001%
10–19 0.2% 0% 0.01% 0.1% 0% 0.01%  < 0.01% 0.0069% 0.001%
20–29 0.2% 0.1% 0.03% 0.3% 0% 0.01% 0.01% 0.031% 0.005%
30–39 0.2% 0.3% 0.07% 0.3 0.1% 0.01% 0.025% 0.084% 0.02%
40–49 0.4% 0.9% 0.2% 0.6% 0.2% 0.12% 0.07% 0.16% 0.05%
50–59 1.3% 2.7% 0.8% 1.5% 0.5% 0.12% 0.29% 0.59% 0.2%
60–69 3.6% 10.8% 4.0% 5.2% 1.4% 0.12% 1.15% 1.93% 0.7%
70–79 8.0% 26.6% 13.5% 14.6% 6.7% 0.12% 3.38% 4.28% 1.9%
80+ 14.8% 34.6% 26.4% 21.8% 21.0% ?** 8.12% 7.8% 8.3%
Overallt 2.3%# 13.8% 3.8% 8.2% 1.6% 0.26%** 0.83% 0.657% 0.5%**
Table 3  SARS-CoV-2 infections, seroprevalence and attack rates in different countries
Country population China (only Hubei) Spain Italy Germany France (only 
French model appl 
[25])
United Kingdom
Population (millions) 57.20 46.94 60.36 83.02 66.99 66.65
Seroprevalence
















Est. Cases and attack rates of SARS-CoV-2
 Cases notified (8/2020) 68,053 250,273 260,307 233,776 223,419 316,371
 Overall CFR 5.2% 7.5% 13.7% 4.0% 13.6% 14.3%
 Cases—lower bound est 0.19 Mio 0.74 Mio 0.96 Mio 0.34 Mio 2.1 Mio 1.75 Mio
 Cases—upper bound est 0.96 Mio 3.18 Mio 4.46 Mio 1.49 Mio 6.0 Mio 8.85 Mio
 Attack rate (min–max) 0.33–1.68% 1.57–6.78% 1.51–7.39% 0.42–1,80% 3.3–9.3% 2.6–13.1%
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based on related models, cohort studies, on national sero-
prevalence studies and outbreaks, which have probably 
been monitored almost completely, e.g., South Korea 
(Table 2) [17, 19, 24, 27, 28].
There is yet no single consenset estimate for the IFR, 
but most models calculate this parameter between 0.5 and 
1 (Table 2) The two models with the lowest values exclude 
especially a group with a high fatality rate, institutional-
ized persons above the age of 80 [24, 27].
IFRs have not been calculated for the most severe Influ-
enza pandemics in the twentieth century (1918, 1957, 1968), 
a direct comparison is thus not possible. Case fatality rates 
for pandemics between 1918 have been estimated by a group 
from the CDC. The CFR of the Influenza 1918 pandemic is 
highest with 2.04, followed by 0.1–0.3 for Influenza 1957 
and up to 0.05 for Influenza 1968 [29].
All current estimates for the CFR of COVID-19 (except 
in countries with probably incomplete mortality data) are 
higher than the CFR for Influenza 1918. In addition, organ 
replacement therapy had not been established widely in the 
time of any of these pandemics. Taking the 25% mortality 
rate of COVID-19 patients requiring invasive ventilation, 
for a direct comparison of CFRs the COVID-19 CFR would 
have to be multiplied by an appropriate factor (e.g., 4).
But the severity of a pandemic depends not solely on the 
IFR. Severity is also dependent on the age distribution of 
fatalities and the attack rate. In sharp contrast to COVID-19, 
a high mortality rate in younger patients (20–49 years) has 
been reported from Influenza 1918 and the attack rate with 
symptomatic cases was between 9 and 40%, higher than for 
almost all national COVID-outbreaks so far (Table 3) [29].
Severity of an epidemic can also be measured by excess 
mortality. Excess mortality due to COVID-19 has been 
reported from a number of regions, e.g., 24 nations from 
Europe with 185,000 excess deaths in the first 18 weeks of 
2020 [30]. No excess mortality, but a signal of COVID mor-
tality can be seen in German weekly deaths, a week signal 
for Germany (Fig. 3a), a pronounced signal for the two states 
with the highest incidence (Fig. 3b) and no signal for the two 
states with the lowest incidence of SARS-CoV-2 (Fig. 3b) 
[31].
Spread of SARS‑CoV‑2 and attack rates 
in the first wave
SARS-CoV-2 has rapidly spread worldwide in the last 9 
months. WHO declared COVID-19 as a pandemic in March 
2020. Strict control measures have limited outbreaks in some 
Asian countries, e.g., China, Korea, Vietnam and Thailand, 
but SARS-CoV-2 outbreaks have been reported in a large 
number of nations [32]. At the end of April 2020 3 million 
cases and 200,000 deaths had been reported worldwide, at 
the end of august 2020 over 25 Mio infections and 800,000 
deaths have occurred [1].
National or regional attack rates can be measured by sero-
prevalence studies or estimated using IFR models (Table 3). 
Seroprevalence studies from different nations differ widely, 
with additional variation between regions (Table 3) [19, 33, 
34, 12, 20, 21].
Using age dependent case fatality rates and adjustment 
by age-dependent infection fatality rates, attack rates can 
be estimated. Using the models of listed in Table 2, we cal-
culated minimum and maximum case numbers in different 
age categories and summarized them to the upper and lower 
bounds of infections and attack rates (Table 3).
These estimates are consistent with seropravelence stud-
ies and demonstrate, that even in outbreaks leading to over-
flow of ICU capacities, the actual attack rate has been low 
(e.g., Lombardy with 7%), lower than for most of the Influ-
enza pandemics. For Germany we estimate the attack rate 
between 0.4 and 1.6% (Table 3). All attack rates measured 
or estimated so far are too low to induce a protective herd 
immunity.
Fig. 3  a, b Weekly deaths 2018-5/2020 in a Germany and two 
regions, b Bavaria plus Baden-Württemberg (combined, blue line) (c) 
Mecklenburg-Vorpommern plus Saxonia-Anhalt combined, red line), 
adjusted for population size by factor 4.5 (weekly deaths in means 
over 2  weeks. Period with deaths due to COVID shaded in gray 
(weeks 8–20/20,209)
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Control and prevention of COVID‑19
Following the outbreak in Wuhan, the province Hubei was 
isolated completely in February 2020. Citizens were neither 
able to leave or reach the province. A curfew was installed, 
infected persons were isolated and close contacts quaran-
tined. Some of these measures were also implemented in 
other Chinese cities and regions, where smaller outbreaks 
occurred following the new year festivities in China. At the 
start of control measures 5000 cases were notified, these rose 
to 70,000 in March. Afterwards the number of cases dropped 
dramatically, and since April, only singular cases or small 
clusters have been reported from China.
Contact restrictions should have an effect on transmission 
and reduce Rt. With a reduction of Rt below 1, an outbreak 
can be controlled.
A group from the Imperial College of London has evalu-
ated control measures and lockdowns in several countries 
in Europe. They have found large effects of these measures, 
putting an end to a first wave of spreading until May 2020. 
The effect of single measures in bundle interventions are 
more difficult to determine and most countries have imple-
mented similar measures. The comparison of the CFRs 
between COVID-19 and Influenza pandemics is a reminder, 
that control and prevention measures should be kept at a 
high level.
Conclusion
SARS-CoV-2 is a newly emerged coronavirus. Human infec-
tions have first been detected in late 2019 in Wuhan, China. 
In the months following, the virus has rapidly spread world-
wide. SARS-CoV-2 replicates mainly in the upper and lower 
respiratory tract and is highly infectious. Droplets and aero-
sol are the main routes of transmission and infection occurs 
also through asymptomatic infected individuals. Nearly 90% 
of cases are uncomplicated, in a minority of cases severe dis-
ease and complications occur. Risk factors for severe disease 
are older age, hypertension, diabetes mellitus, chronic heart 
or pulmonary disease, and immunodeficiency.
A first wave of COVID-19 has be reported in most Euro-
pean countries between February and May 2020, leading to 
high excess mortality. Control measures restricting social 
contacts, travel activities and commerce have lead to control 
of outbreaks in many countries with a high efficacy.
The current case-fatality rates in most countries are 
higher than for known Influenza pandemics, but the fatality 
rates in younger people and the attack rates in most countries 
are lower than in the most severe, the Influenza 1918.
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